Literature DB >> 19935671

Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy.

Li-Xin Zhou1, Tao Li, Yi-Ran Huang, Jian-Jun Sha, Peng Sun, Dong Li.   

Abstract

The role of histone modifications in the development and progression of cancer remains unclear. Here, we gave an investigation of the relationship between the various histone modifications and the risk prediction of the biochemical recurrence after radical prostatectomy (RP). Histone 3 lysine 4 dimethylation (H3K4diMe), trimethylation (H3K4triMe), lysine 36 trimethylation (H3K36triMe), histone 4 lysine 20 trimethylation (H4K20triMe) and acetylation of histome 3 lysine 9 (H3K9Ac) were evaluated using immnuohistochemistry coupled with the tissue microarray technique in 169 primary prostatectomy tissue samples. Recursive partitioning analysis (RPA) was used to analyze the data. Through global histone modification analysis in patients who underwent radical prostatectomy, we found that H3K4triMe can predict the risk of the biochemical recurrence for the low grade prostate cancer (Gleason score < or = 6) after RP. In the case of high grade prostate cancer (Gleason score > or = 7), H4K20triMe and H3K9Ac accompanying with the pre-operation prostate-specific antigen (PSA) level could also predict the risk of the biochemical recurrence after RP. In combination with the Gleason score and pre-operation PSA level, the acetylation and methylation of histones H3 and H4 can predict the biochemical recurrence of the prostate cancer following RP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935671      PMCID: PMC3739095          DOI: 10.1038/aja.2009.81

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  36 in total

1.  Global histone acetylation and deacetylation in yeast.

Authors:  M Vogelauer; J Wu; N Suka; M Grunstein
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

2.  Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis.

Authors:  Hermann Brenner
Journal:  Lancet       Date:  2002-10-12       Impact factor: 79.321

Review 3.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival.

Authors:  W A Sakr; M V Tefilli; D J Grignon; M Banerjee; J Dey; E L Gheiler; R Tiguert; I J Powell; D P Wood
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

Review 5.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

6.  Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma.

Authors:  Yutaka Tokumaru; Susan V Harden; Dong-Il Sun; Keishi Yamashita; Jonathan I Epstein; David Sidransky
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Authors:  Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-07       Impact factor: 11.205

8.  Mapping global histone acetylation patterns to gene expression.

Authors:  Siavash K Kurdistani; Saeed Tavazoie; Michael Grunstein
Journal:  Cell       Date:  2004-06-11       Impact factor: 41.582

9.  Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.

Authors:  Ashish M Kamat; Kara Babaian; Min Rex Cheung; Yoshio Naya; Samuel H Huang; Deborah Kuban; Richard J Babaian
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

10.  Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker.

Authors:  Carmen Jerónimo; Rui Henrique; Mohammad O Hoque; Franclim R Ribeiro; Jorge Oliveira; Daniel Fonseca; Manuel R Teixeira; Carlos Lopes; David Sidransky
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  8 in total

Review 1.  Histone modifications and chromatin organization in prostate cancer.

Authors:  Zhong Chen; Liguo Wang; Qianben Wang; Wei Li
Journal:  Epigenomics       Date:  2010-08       Impact factor: 4.778

2.  A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.

Authors:  Dana E Rathkopf; Joel Picus; Arif Hussain; Susan Ellard; Kim Nguyen Chi; Thomas Nydam; Erin Allen-Freda; Kaushal Kishor Mishra; Maria Grazia Porro; Howard I Scher; George Wilding
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-03       Impact factor: 3.333

3.  Epigenetics in prostate cancer.

Authors:  Costantine Albany; Ajjai S Alva; Ana M Aparicio; Rakesh Singal; Sarvari Yellapragada; Guru Sonpavde; Noah M Hahn
Journal:  Prostate Cancer       Date:  2011-11-30

4.  Alterations of global histone H4K20 methylation during prostate carcinogenesis.

Authors:  Turang E Behbahani; Philip Kahl; Johannes von der Gathen; Lukas C Heukamp; Claudia Baumann; Ines Gütgemann; Bernhard Walter; Ferdinand Hofstädter; Patrick J Bastian; Alexander von Ruecker; Stefan C Müller; Sebastian Rogenhofer; Jörg Ellinger
Journal:  BMC Urol       Date:  2012-03-13       Impact factor: 2.264

Review 5.  Epigenetic reprogramming during prostate cancer progression: A perspective from development.

Authors:  Sakshi Goel; Vipul Bhatia; Tanay Biswas; Bushra Ateeq
Journal:  Semin Cancer Biol       Date:  2021-02-02       Impact factor: 17.012

6.  Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.

Authors:  Shivashankar Damodaran; Nathan Damaschke; Joseph Gawdzik; Bing Yang; Cedric Shi; Glenn O Allen; Wei Huang; John Denu; David Jarrard
Journal:  BMC Cancer       Date:  2017-12-20       Impact factor: 4.430

7.  UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.

Authors:  Xuechao Wan; Shu Yang; Wenhua Huang; Denglong Wu; Hongbing Chen; Ming Wu; Junliang Li; Tao Li; Yao Li
Journal:  J Exp Clin Cancer Res       Date:  2016-02-17

8.  CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions.

Authors:  Molishree Joshi; Gergana E Stoykova; Maren Salzmann-Sullivan; Monika Dzieciatkowska; Lauren N Liebman; Gagan Deep; Isabel R Schlaepfer
Journal:  Cells       Date:  2019-09-20       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.